Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation

OBJECTIVES: To test the potential of fimepinostat (CUDC-907), a dual inhibitor of histone deacetylases (HDAC) and phosphatidylinositol-3-kinases (PI3K), to reverse human immunodeficiency virus type 1 (HIV-1) latency in infected cell lines and in CD4+ T cells from HIV-1-infected donors on long-term c...

Descripción completa

Detalles Bibliográficos
Autores principales: Gunst, Jesper D, Kjær, Kathrine, Olesen, Rikke, Rasmussen, Thomas A, Østergaard, Lars, Denton, Paul W, Søgaard, Ole S, Tolstrup, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mediscript Ltd 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816120/
https://www.ncbi.nlm.nih.gov/pubmed/31700655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816120/
https://www.ncbi.nlm.nih.gov/pubmed/31700655

Ejemplares similares